Dr. CYJ Hair Filler 2x1ml
Important Notice
Medical device regulated by the European Medical Device Regulation (MDR), intended exclusively for authorized healthcare professionals. By purchasing, the customer declares to be authorized for their professional activity; false information may entail legal responsibilities.
DR. CYJ Hair Filler is the injectable hair treatment from Caregen Co., Ltd. (South Korea), developed by Dr Yong Ji Chung on the basis of the company's biomimetic peptide technology. It combines seven synthetic peptides directed at different pathways of follicle biology with a hyaluronic acid vehicle that prolongs their residence in the dermis of the scalp. It is not a volumetric filler: it is applied as intradermal microinjections following a protocol of fortnightly sessions.
- Active complex of 7 peptides
- Vehicle hyaluronic acid
- Contents 2 syringes × 1.0 ml
- Needle 30G–32G
- Protocol 4 sessions / every 2 weeks
Composition and technology
- Patented peptide complex of seven synthetic peptides: decapeptide-18, decapeptide-10, decapeptide-28, octapeptide-2, octapeptide-11, oligopeptide-54 and oligopeptide-71. Each acts on a different pathway of follicular biology — stimulation of the follicle stem cells, prolongation of the anagen phase, anti-inflammatory effect and reduction of shedding.
- Hyaluronic acid as a vehicle: it keeps the peptide complex in the dermal plane and prolongs its contact time with the follicle compared with a simple aqueous solution.
- Biomimetic peptide technology: the peptides reproduce sequences of endogenous growth factors and signalling molecules, with the aim of acting on the same receptors.
Indications and treatment areas
Injectable product indicated for the treatment of the scalp in adult patients.
- Androgenetic alopecia
- Telogen effluvium
- Weakening and thinning of the hair shaft
- Loss of hair density
- Scalp with chemical or thermal damage
Technique and treatment protocol
- Preparation: mark the treatment areas and disinfect the scalp before application.
- Needle: 30G–32G.
- Angle and plane: insert at an angle of approximately 30° to the surface of the scalp, in the superficial to mid dermis.
- Distribution of the points: points spaced 0.2 to 0.3 cm apart within a 1 cm line.
- Volume per point: 0.02–0.05 ml.
- Application: apply uniform pressure to the plunger during injection.
- Standard protocol: 4 sessions, one every 2 weeks, over 8 weeks.
- Maintenance: monthly sessions for 3 to 6 months after completing the initial regimen.
- Onset of the result: the first changes are observed between 2 and 3 weeks after the fourth session; the full effect is established over 2 to 3 months.
The pack of 2 syringes of 1.0 ml covers two sessions of the standard regimen.
Technical data
| Manufacturer | Caregen Co., Ltd. — South Korea |
|---|---|
| Active substance | Complex of 7 synthetic peptides (decapeptide-18, decapeptide-10, decapeptide-28, octapeptide-2, octapeptide-11, oligopeptide-54, oligopeptide-71) |
| Vehicle | Hyaluronic acid |
| Presentation | 2 pre-filled syringes of 1.0 ml |
| Needle | 30G–32G |
| Injection plane | Superficial to mid dermis of the scalp |
| Protocol | 4 sessions, one every 2 weeks |
| Use | Exclusively qualified healthcare professionals with specific training |
Storage and pack contents
- Storage: keep in the original packaging, protected from light, under the temperature conditions indicated on it. Do not freeze.
- Do not use after the expiry date shown on the packaging.
- Sterile single-use product. Do not reuse or resterilise.
- The pack contains: 2 pre-filled syringes of 1.0 ml, instructions for use and traceability labels.
Contraindications and warnings
Contraindications: pregnancy and breastfeeding; under 18 years of age; known hypersensitivity to any of the components of the formulation; active infection or inflammation of the scalp; active dermatosis in the treatment area.
Caution: assess individually in patients on anticoagulant or antiplatelet therapy.
Expected reactions: redness, oedema, pruritus and mild discomfort in the treated area, transient in nature and usually resolved within 72 hours.
The manufacturer restricts use to professionals with specific training or working in accredited centres. Always consult the instructions for use included in the pack before application.
Product intended exclusively for qualified healthcare professionals. Technical information based on the documentation of the manufacturer Caregen Co., Ltd. and of its official distribution. This data sheet does not replace the instructions for use accompanying the product.